Seer(NASDAQ) SEER

Market Cap$122.80M

Since IPO (2020)-96%

5 Year-93%

1 Year+5%

1 Month+36%

$2.21

+7.28%

+0.15Today

After hours$2.21+$0.00 (+0.00%)

Seer last closing stock price
Metric	Price	Date
Last close	USD 2.22	2026-07-31

Seer stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+12.69%	USD 1.97	2026-07-24
1 month	+36.2%	USD 1.63	2026-07-01
3 month	+9.36%	USD 2.03	2026-05-01
Year to date	+21.31%	USD 1.83	2025-12-31
1 year	+4.72%	USD 2.12	2025-07-31
3 year	-54.23%	USD 4.85	2023-08-01
5 year	-93.05%	USD 31.94	2021-07-30
Since inception	-96.07%	USD 56.46	2020-12-04

Seer Financials at a Glance

Market Cap

$122.80M

Revenue (TTM)

$14.68M

Net Income (TTM)

-$70.49M

EPS (TTM)

-$1.24

P/E Ratio

-1.78

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Price

$2.21

Volume

2,903,582.979

Open

$2.21

Price

$2.21

Volume

2,903,582.979

Open

$2.21

Previous Close

$2.22

Daily Range

$2.16 - $2.25

52-Week Range

$1.55 - $2.41

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

1.67 (High)

Price

$2.21

Volume

2,903,582.979

Open

$2.21

Previous Close

$2.22

Daily Range

$2.16 - $2.25

52-Week Range

$1.55 - $2.41

Estimated Earnings Date

Aug 5, 2026

SEER News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Seer

Seer, Inc. is a leading company in next-generation proteomics, focused on advancing life sciences through innovative protein analysis technology. Its flagship platform, the Proteograph™, utilizes advanced nanoparticle technology to achieve high-depth, unbiased proteomic analyses. This positions Seer as a key player in the field, offering a compelling alternative to traditional methods.

Products and Services

Proteograph™ Platform: A proprietary technology for advanced proteomic analyses.

Applications in Biomarker Discovery: Facilitates the identification of disease indicators.

Drug Development Support: Enhances the precision of pharmaceutical research.

Diagnostics: Improves accuracy in detecting various conditions.

What Makes Seer, Inc. Special

Seer leverages proprietary nanoparticle technology to provide deep and unbiased protein analysis, unmatched by traditional methods. This approach offers enhanced scalability, depth, and accuracy, positioning Seer as a leader in transforming proteomics.

Five Things You Need to Know

Seer leads in next-generation proteomics with its innovative Proteograph™ platform.

The company differentiates itself through a platform that enables deep, unbiased protein analysis.

Seer aims to broaden platform adoption across biomarker discovery, drug development, and diagnostics.

Its leadership team has extensive experience in biotechnology innovation and commercialization.

Seer is positioned for substantial growth as the demand for sophisticated biological insights increases.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

124

CEO

Omid C. Farokhzad, MD, MBA

Website

www.seer.bio

Headquarters

Redwood City, CA 94065, US

SEER Financials

Key Financial Metrics (TTM)

Gross Margin

47.00%

Operating Margin

-507.61%

Net Income Margin

-480.17%

Return on Equity

-26.58%

Return on Capital

-27.56%

Return on Assets

-25.90%

Earnings Yield

-56.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$122.80M

Shares Outstanding

55.32M

Volume

2.90M

Avg. Volume

1.10M

Financials (TTM)

Gross Profit

$6.90M

Operating Income

-$74.52M

EBITDA

-$68.48M

Operating Cash Flow

-$48.47M

Capital Expenditure

-$1.41M

Free Cash Flow

-$49.88M

Cash & ST Invst.

$166.67M

Total Debt

$23.03M

Seer Performance Analysis

Seer annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 14,685,000	129.7%
2023	2023-12-31	USD 15,182,000	3.4%
2024	2024-12-31	USD 13,947,000	-8.1%
2025	2025-12-31	USD 16,119,000	15.6%

Seer sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-5.1%
Q3	2025-09-30	0.9%
Q4	2025-12-31	2.6%
Q1	2026-03-31	-33.6%

Seer annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.49	27.3%
2023	2023-12-31	USD -1.35	-9.3%
2024	2024-12-31	USD -1.39	2.8%
2025	2025-12-31	USD -1.28	-7.8%

Seer sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	2.9%
Q3	2025-09-30	3.0%
Q4	2025-12-31	9.4%
Q1	2026-03-31	-3.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$2.71M

-34.7%

Gross Profit

$895.00K

-55.3%

Gross Margin

33.07%

N/A

Market Cap

$122.80M

N/A

Market Cap/Employee

$990.33K

N/A

Employees

124

N/A

Net Income

-$16.84M

+15.6%

EBITDA

-$15.73M

+17.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$166.67M

-30.5%

Total Debt

$23.03M

-9.4%

Accounts Receivable

$4.26M

-20.5%

Inventory

$8.08M

+14.3%

Long Term Debt

$20.38M

-11.5%

Short Term Debt

$2.64M

+11.3%

Return on Assets

-25.90%

N/A

Return on Invested Capital

-28.45%

N/A

Free Cash Flow

-$15.71M

-30.1%

Operating Cash Flow

-$15.44M

-35.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PEPGPepGen Inc.

PEPGPepGen Inc.$1.76-1.12%

QSIQuantum-Si incorporated

QSIQuantum-Si incorporated$0.71-1.06%

NKTXNkarta, Inc.

NKTXNkarta, Inc.$2.09-2.79%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$4.15+5.60%

MNOVMediciNova, Inc.

MNOVMediciNova, Inc.$1.33-0.75%

ANTXAN2 Therapeutics, Inc.

ANTXAN2 Therapeutics, Inc.$5.35+0.38%

GBIOGeneration Bio Co.

GBIOGeneration Bio Co.$5.34+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About SEER

What is the current price of Seer?

Seer is trading at $2.22 per share.

What is the 52-week range for Seer?

Over the past 52 weeks, Seer has traded between $1.55 and $2.41.

How much debt does Seer have?

As of the most recent reporting period, Seer reported total debt of $23.03M.

How much cash does Seer have on hand?

Seer reported $47.32M in cash and cash equivalents in its most recent financial results.

What is Seer’s dividend yield?

Seer does not currently have a dividend yield.

Seer(NASDAQ) SEER

Seer Financials at a Glance

SEER News

Seer (SEER) Q2 Revenue Jumps 32%

Why Shares of Seer Are Slumping Wednesday

CEO of Newly IPO'd Seer: For Biotech Investors, Proteins Are The New DNA

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Seer

Products and Services

What Makes Seer, Inc. Special

Five Things You Need to Know

SEER Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Seer Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SEER

What is the current price of Seer?

What is the 52-week range for Seer?

How much debt does Seer have?

How much cash does Seer have on hand?

What is Seer’s dividend yield?

Premium Investing Services